Edgar Snyder & Associates®
A Law Firm Representing Injured People
Call Us Toll Free 24/7
Published on May 05, 2006 by Edgar Snyder

Ketek Approved Despite Flawed Study


The death of a 26-year-old construction worker who died from severe liver damage after taking the antibiotic Ketek has prompted a government investigation. An internal Food and Drug Administration (FDA) analysis reported ten cases of people sustaining liver failure after taking the antibiotic. Now documents have surfaced, including internal Aventis emails, piquing interest about a key clinical trial for Ketek, known as study 3014.

Aventis began the study in 2001 at the request of the FDA, due to concerns about liver damage, blurry vision and other possible side effects, after reviewing the company’s earlier trials. The FDA later declared that study 3014 had so many flaws that the data was not reliable. Despite the flawed study, the FDA went on to approve the drug to treat sinusitis, bronchitis and pneumonia in April 2004.

Sanofi-Aventis is the third largest drug manufacturer, and last year alone 3.35 million pescriptions were written for Ketek. Currently, the drug is being studied in children with ear infections and tonsillitis. Sanofi-Aventis maintains the drug is safe.

For more information about dangerous drugs, visit our Dangerous Drug and Recall Legal Center.

Drug litigation may involve co-counsel.

Source: “Fraud Errors, Taint Key Study Of Widely Used Sanofi Drug.” By Anna Wilde Mathews. The Wall Street Journal. May 01, 2006.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
Briefly describe your injuries

Recent News

Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers